Related Experiment Video
Updated: Aug 10, 2025

Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Reducing Diabetic Ketoacidosis Readmissions with a Hospital-School-Based Improvement Partnership
Zoe M King1, Jordan E Kurzum2, Mary Reich Cooper3
1Nemours Children's Hospital, Delaware, Wilmington, DE.
Insights
Missed basal insulin doses frequently cause diabetic ketoacidosis (DKA) readmissions in children with type 1 diabetes mellitus (T1D). A school nurse intervention using insulin degludec reduced DKA readmissions by 31%.
Area of Science:
- Pediatrics
- Endocrinology
- Diabetes Management
Background:
- Diabetic ketoacidosis (DKA) is a major cause of illness and death in children with type 1 diabetes mellitus (T1D).
- A significant majority of DKA readmissions (76.4%) were linked to missed basal insulin doses.
- Identifying and addressing missed basal insulin is critical for preventing recurrent DKA hospitalizations.
Purpose of the Study:
- To implement and evaluate a quality improvement initiative aimed at reducing DKA readmissions in pediatric T1D patients.
- To investigate the effectiveness of a standardized intervention involving school-based nurses and insulin degludec for managing basal insulin adherence.
- To assess the impact of this intervention on the rate of DKA readmissions.
Main Methods:
- Quality improvement tools were employed to design and implement process changes focused on basal insulin management.
- The intervention specifically utilized insulin degludec and engaged school-based nurses to address missed basal insulin dosing.
- Data on DKA readmission rates were collected and analyzed before and after the intervention period.
Main Results:
- The DKA readmission rate decreased by 31%, from an average of 5.25 per month to 3.64 per month.
- This reduction was observed over an 11-month intervention period (May 2019 to March 2020).
- The intervention demonstrated a significant decrease in DKA readmissions attributed to missed basal insulin.
Conclusions:
- A standardized approach incorporating school-based nursing support and insulin degludec effectively reduces DKA readmissions in pediatric T1D.
- This intervention is a safe and effective strategy for improving basal insulin adherence and lowering hospitalization rates.
- The findings highlight the importance of targeted interventions in managing chronic conditions like T1D in pediatric populations.
Abstract:
Diabetic ketoacidosis (DKA) is the leading cause of morbidity and mortality in pediatric type 1 diabetes mellitus (T1D). Baseline data showed 139 of 182 DKA readmissions (76.4%) were due to missed basal insulin dosing. The team used quality improvement tools to implement a process change around basal insulin. The project utilized insulin degludec and school-based nurses when missed basal insulin was noted as a main driver for readmission. The DKA readmission rate averaged 5.25 per month from January 2017 to April 2019. The rate decreased to 3.64 per month during the intervention from May 2019 to March 2020, a 31% reduction over 11 months. This standardized approach for patients with T1D readmitted with DKA, using a school-based intervention and insulin degludec, reduced the number of DKA readmissions. This method is safe and effective for lowering DKA readmissions due to missed basal insulin in areas with reliable school nursing.
Related Concept Videos
SBAR II: Application of SBAR
SBAR Report from a Nurse to a Health Care Provider
S: "Hello, Dr. Smith. This is Jane, RN, from the Med Surg unit. I am calling to tell you about Ms. White in Room 210, who is experiencing increased pain and redness at her incision site. Her recent...
Chronic Kidney Disease III: Interprofessional Care
Chronic Pancreatitis II: Collaborative Care
Assessment:
Healthcare Associated Infections II: Preventive Measures
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Dipeptidyl Peptidase 4 Inhibitors

